Cargando…

EGFR-directed antibodies increase the risk of severe infection in cancer patients

Monoclonal antibodies directed to the epidermal growth factor receptor (EGFR) have a role in the management of several solid tumors, alone or in combination with chemotherapy or radiation therapy. Recognized toxicities have included hypersensitivity reactions, rash, hypomagnesemia, and constitutiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Altan, Mehmet, Burtness, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336483/ https://www.ncbi.nlm.nih.gov/pubmed/25857245 http://dx.doi.org/10.1186/s12916-015-0276-9

Ejemplares similares

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
por: Palmieri, Giuseppe, et al.
Publicado: (2017)

Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis?
por: Kalil, Andre C, et al.
Publicado: (2011)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

COVID-19: Reducing the risk of infection might increase the risk of intimate partner violence
por: van Gelder, N., et al.
Publicado: (2020)

Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors
por: Yokoyama, Hiroki
Publicado: (2020)

Baseline endothelial-related biomarkers in hemodialysis patients and risk of developing severe SARS-Cov-2 infection
por: Gomes, Cícero Abdon Malheiro, et al.
Publicado: (2021)

Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer
por: Kim, Donghwa, et al.
Publicado: (2021)

Immunodepression in the surgical patient and increased susceptibility to infection
por: Volk, Hans-Dieter
Publicado: (2002)

Risk management in patients with severe acute pancreatitis
por: Gerlach, Herwig
Publicado: (2004)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Reporting research antibody use: how to increase experimental reproducibility
por: Helsby, Matthew A, et al.
Publicado: (2013)

Introducing cancers of the head and neck, a new open access journal
por: Burtness, Barbara
Publicado: (2016)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Anti‐EGFR Therapy in Small Bowel Adenocarcinoma
por: Safyan, Rachael A., et al.
Publicado: (2018)

One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer
por: Breadner, Daniel, et al.
Publicado: (2020)

COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease
por: Moey, Melissa Y.Y., et al.
Publicado: (2023)

Age‐adapted eGFR thresholds underestimate the risks beyond kidney failure associated with CKD in older populations
por: Lees, Jennifer S., et al.
Publicado: (2022)

An evolutionary explanation for antibiotics’ association with increased colon cancer risk
por: Voskarides, Konstantinos
Publicado: (2022)

Commentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection
por: Gujral, Jasmine, et al.
Publicado: (2022)

EGFR mutation testing from pleural effusions of non-small cell lung cancer patients at the institute for oncology and radiology of Serbia
por: Vukovic, Miodrag, et al.
Publicado: (2023)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

“Early goal-directed therapy” versus “Early” and “goal-directed” therapy for severe sepsis and septic shock: Time to rationalize
por: Dhooria, Sahajal, et al.
Publicado: (2015)

COX-2 and EGFR: Partners in Crime Split by Aspirin
por: Patrignani, Paola, et al.
Publicado: (2015)

Regulation of EGFR surface levels by COPII-dependent trafficking
por: Farhan, Hesso
Publicado: (2016)

Modeling therapy resistance via the EGFR signaling pathway
por: Plattner, Christina, et al.
Publicado: (2019)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Does acupuncture increase the risk of bleeding in patients taking warfarin?
por: Leem, Jungtae
Publicado: (2015)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
por: Stefanski, Casey D., et al.
Publicado: (2022)

Increased blood flow by insulin infusion targeting normoglycemia in patients with severe sepsis: friend or foe?
por: Berghe, Greet Van den
Publicado: (2010)

Commentary: Expression of p53 and Ki-67 proteins in patients with increasing severity and duration of pterygium
por: Arora, Ritu
Publicado: (2021)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy
por: Abcouwer, Steven F.
Publicado: (2013)

The increasing significance of disease severity in a burden of disease framework
por: Wyper, Grant M.A., et al.
Publicado: (2021)

The Complexity of Antibody-Dependent Enhancement of Dengue Virus Infection
por: Guzman, Maria G., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7aavf9ncvk5u82eloarkbbjlpd